Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience

Conclusion Our prospective data confirm that anti-angiogenic drugs are active in SFT. PFS and overall response do not appear significantly lower than other reported series on the same disease. Furthermore, pazopanib is a drug already licensed in soft tissue sarcomas and these data suggest its activity also in this particular subtype of sarcomas.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research